Screener
Krystal Biotech, Inc. KRYS Europe — Product revenue, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
FAQ
- What is Krystal Biotech, Inc.'s europe — product revenue, net?
- Krystal Biotech, Inc. (KRYS) reported europe — product revenue, net of $20.68M in Q1 2026.
- What does europe — product revenue, net mean?
- This metric represents the total net sales generated from the sale of pharmaceutical products within the European geographic market. It reflects the company's ability to successfully commercialize its gene therapy platform and navigate regulatory and reimbursement landscapes in European territories. This figure is calculated after accounting for returns, rebates, and other sales-related deductions.
Ask your AI about Krystal Biotech, Inc.'s europe — product revenue, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude